bone marrow, Haematological diseases; any disorder that primarily affects the blood, the lymphatic system and/or blood-forming organs.
Conditions
Brief summary
Overall survival (OS)
Detailed description
Progression free survival (PFS), Patient-reported health-related quality of life (HRQoL), Number and type, seriousness and relationship to study treatments of AEs, vital signs, and clinical laboratory results, as indicated in the DSA., Planned hospital admission with no emergency room visit; Unplanned hospital admission with no emergency room visit and with emergency room visit; Length of hospital stay; Length of any time spent in an intensive care unit; mergency room visit only; Outpatient/physician office attendance; Physician/nurse telephone contact visit, Exposure to trial medicinal products; Treatment duration
Interventions
DRUGIBRUTINIB
DRUGZANUBRUTINIB
Sponsors
Region Hovedstaden
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival (OS) | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression free survival (PFS), Patient-reported health-related quality of life (HRQoL), Number and type, seriousness and relationship to study treatments of AEs, vital signs, and clinical laboratory results, as indicated in the DSA., Planned hospital admission with no emergency room visit; Unplanned hospital admission with no emergency room visit and with emergency room visit; Length of hospital stay; Length of any time spent in an intensive care unit; mergency room visit only; Outpatient/physician office attendance; Physician/nurse telephone contact visit, Exposure to trial medicinal products; Treatment duration | — |
Outcome results
None listed